FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer

David J. Hoopes, Mark Tann, James W. Fletcher, Jeffrey A. Forquer, Pei Fen Lin, Simon S. Lo, Robert D. Timmerman, Ronald C. McGarry

Research output: Contribution to journalArticle

134 Scopus citations

Abstract

Purpose: To investigate the utility of positron emission tomography (PET) in patients treated with stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer (NSCLC) on prospective institutional trials. Patients and methods: Fifty-eight patients with medically inoperable stage I NSCLC who participated in prospective phase I and II trials of SBRT, had ≥2 years of follow-up, and received FDG-PET imaging are the focus of this evaluation. Fifty-seven of 58 patients received pre-SBRT FDG-PET to confirm stage I status. All patients received stereotactic body frame immobilization and treatment with 7-10 photon beams. SBRT total doses ranged from 24 to 72 Gy in three fractions. No elective nodal irradiation was undertaken. Regular follow-up with planned CT imaging was performed on all patients. Post-SBRT FDG-PET was not mandated by protocol and was typically ordered upon concern for disease recurrence. Thirty-eight post-SBRT PET studies were performed in 28 patients at a median 17.3 months following SBRT. Results: With a median follow-up of 42.5 months, the 3-year actuarial overall survival and local control for this select subset of our SBRT experience were 48.9% and 74.8%, respectively. Pre-SBRT FDG-PET SUV did not predict 3-year overall survival or local control. Fourteen of 57 patients eventually failed in nodal stations by CT and/or PET. Isolated first site of failure was nodal in 6 patients (10%). Out of 28 patients with post-SBRT PET, 4 (14%) had delayed PET imaging (22-26 months after SBRT) showing moderate hypermetabolic activity (SUV 2.5-5.07), but no evidence of local, nodal, or distant recurrence by clinical examination and conventional imaging performed 20-26 months following these concerning PET findings. Conclusions: Isolated nodal recurrence following PET-staged I NSCLC treated with SBRT is uncommon. Moderate post-SBRT PET hypermetabolic activity may persist 2 years following treatment without definite evidence of recurrence. Further study is needed to confirm these results in larger populations with longer follow-up.

Original languageEnglish (US)
Pages (from-to)229-234
Number of pages6
JournalLung Cancer
Volume56
Issue number2
DOIs
StatePublished - May 1 2007

    Fingerprint

Keywords

  • Hypofractionation
  • Isolated nodal recurrence
  • Lung cancer
  • Non-small-cell
  • Persistent hypermetabolic activity
  • PET
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Hoopes, D. J., Tann, M., Fletcher, J. W., Forquer, J. A., Lin, P. F., Lo, S. S., Timmerman, R. D., & McGarry, R. C. (2007). FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer, 56(2), 229-234. https://doi.org/10.1016/j.lungcan.2006.12.009